# Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

> **NCT01706120** · PHASE4 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 400 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01706120
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706120, "Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01706120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*